Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been assigned a consensus rating of “Moderate Buy” from the four analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $98.75.

Several research analysts have commented on PBH shares. DA Davidson lifted their price target on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Canaccord Genuity Group restated a “buy” rating and issued a $80.00 price target on shares of Prestige Consumer Healthcare in a research note on Tuesday, May 21st. Finally, StockNews.com cut shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a report on Tuesday, May 21st.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of institutional investors have recently modified their holdings of the stock. Sanctuary Advisors LLC acquired a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter worth about $1,095,000. Brandes Investment Partners LP raised its position in shares of Prestige Consumer Healthcare by 9.0% during the second quarter. Brandes Investment Partners LP now owns 165,293 shares of the company’s stock worth $11,447,000 after purchasing an additional 13,643 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after purchasing an additional 433 shares during the period. Algert Global LLC lifted its position in shares of Prestige Consumer Healthcare by 50.7% in the second quarter. Algert Global LLC now owns 14,873 shares of the company’s stock worth $1,024,000 after purchasing an additional 5,003 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Prestige Consumer Healthcare by 0.8% in the second quarter. The Manufacturers Life Insurance Company now owns 543,401 shares of the company’s stock valued at $37,413,000 after purchasing an additional 4,305 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Down 0.2 %

Prestige Consumer Healthcare stock opened at $73.55 on Wednesday. The firm has a market capitalization of $3.65 billion, a P/E ratio of 17.64, a P/E/G ratio of 2.06 and a beta of 0.48. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.65. Prestige Consumer Healthcare has a twelve month low of $56.34 and a twelve month high of $75.80. The stock’s fifty day simple moving average is $70.98 and its 200-day simple moving average is $69.61.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 8th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.86 by $0.04. The firm had revenue of $267.10 million for the quarter, compared to analyst estimates of $260.54 million. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. Prestige Consumer Healthcare’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.06 earnings per share. As a group, equities analysts expect that Prestige Consumer Healthcare will post 4.42 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.